首页> 外文期刊>Antimicrobial agents and chemotherapy. >Pharmacokinetics of single-dose oral stavudine in subjects with renal impairment and in subjects requiring hemodialysis.
【24h】

Pharmacokinetics of single-dose oral stavudine in subjects with renal impairment and in subjects requiring hemodialysis.

机译:单剂量口服司他夫定在肾功能不全患者和需要血液透析的患者中的药代动力学。

获取原文
获取原文并翻译 | 示例

摘要

Two open-label studies assessed the pharmacokinetics of single orally administered doses of 40 mg of stavudine in subjects with renal impairment. In one study (study I), 15 subjects with selected degrees of renal impairment, but not requiring hemodialysis, were stratified into three groups of five subjects each according to creatinine clearance (CL(CR)) normalized by body surface area (ml/min/1.73 m(2)): mild (CL(CR), 60 to 80), moderate (30 to 50), and severe (/= 90) were also enrolled. The stavudine area under the curve from 0 h to infinity (AUC(0-infinity)) increased nonlinearly with declining renal function: 1,864, 2,215, 3,609, and 5,928 ng. h/ml for normal renal function and for mild, moderate, and severe renal impairment, respectively (P = 0.0001 between renal impairment groups). The following stavudine dosage recommendations for renal impairment were proposed for subjects weighing >/=60 kg: CL(CR) of >50 ml/min/1.73 m(2), 40 mg every 12 h; CL(CR) of 21 to 50 ml/min/1. 73 m(2), 20 mg every 12 h; and CL(CR) of 10 to 20 ml/min/1.73 m(2), 20 mg every 24 h. For subjects weighing <60 kg, the proposed doses were 30, 15, and 15 mg, respectively, with the same dosing intervals specified above. In a second study (study II), 12 subjects with end-stage renal disease requiring hemodialysis three times a week were enrolled in a randomized, open-label crossover study (dialysis 2 h after dosing and lasting 4 h or dosing without dialysis). There were no statistically significant differences for AUC(0-infinity), AUC(2-6), time to maximum concentration of drug in serum, half-life, or apparent oral clearance when the two treatment dosage regimens were compared. As a result of study II, the recommended dosing rate for subjects requiring hemodialysis was the same as that proposed for those with severe renal impairment not requiring hemodialysis; however, dosing was recommended to follow hemodialysis and to occur at the same time each day.
机译:两项开放标签研究评估了单剂量口服40 mg司他夫定对肾功能不全患者的药代动力学。在一项研究(研究I)中,根据肌酐清除率(CL(CR))将15例具有一定程度的肾功能不全但无需进行血液透析的受试者分为三组,每组五个受试者,肌酐清除率以体表面积(ml / min)归一化/1.73 m(2)):轻度(CL(CR),60至80),中度(30至50)和严重( / = 90)。从0小时到无限远(AUC(0-无限))曲线下的司他夫定面积随肾功能下降而非线性增加:1,864、2,215、3,609和5,928 ng。正常肾功能和轻度,中度和重度肾功能不全的h / ml(肾功能不全组之间P = 0.0001)。对于体重> / = 60 kg的受试者,提出了下列司他夫定剂量推荐用于肾脏损害:CL(CR)> 50 ml / min / 1.73 m(2),每12小时40 mg; CL(CR)为21至50 ml / min / 1。 73 m(2),每12小时20 mg; CL(CR)为10至20 ml / min / 1.73 m(2),每24小时20 mg。对于体重<60 kg的受试者,建议的剂量分别为30、15和15 mg,并具有与上述相同的给药间隔。在第二项研究(研究II)中,将12名每周需进行3次血液透析的终末期肾脏疾病的受试者纳入一项随机,开放标签的交叉研究(给药后2小时透析,持续4 h或不进行透析给药)。比较两种治疗剂量方案时,AUC(0-无穷大),AUC(2-6),达到最大药物浓度的时间,半衰期或表观口腔清除率无统计学差异。研究II的结果是,需要血液透析的受试者的推荐给药率与那些不需血液透析的严重肾功能不全者的推荐给药率相同。但是,建议在血液透析后每天服用一次。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号